RESEARCH PAPER

Patent Law And Generic Drug Industry In India: Legal Perspectives On Accessibility And Innovation

Hiya Das[1], Ajoy Kumar Sardar[2], Bidismita Ojha[3], Bidisha Das[4], Hemangana Deuri[5], Krishna Pathak[6]

[1] Assistant Professor, Royal School of Law and Administration, The Assam Royal Global University, Guwahati. Email: hiyadas761@gmail.com

[2] PhD Scholar, Department of Law, North-Eastern Hill University, Shillong, Meghalaya. Email: ajoykrsardar1995@gmail.com

[3] Assistant Professor in Law, Barpeta Law College, Barpeta, Assam. Email: ojahbidismita@gmail.com

[4] Assistant Professor in Law, Barpeta Law College, Barpeta, Assam. Email: bididas02@gmail.com

[5] Assistant Professor in Law, Barpeta Law College, Barpeta, Assam. Email: deurihemangana@gmail.com

[6] Assistant Professor in Sociology, Barpeta Law College, Barpeta, Assam. Email: kpbarpeta1@gmail.com

Received: 2nd Mar, 2026 | **Revised:** 14th Mar, 2026 | **Accepted:** 4th Apr, 2026 | **Available Online:** 20th Apr, 2026

ABSTRACT

The drug industry and patent law of India are a crucial field of inquiry that represents the complicated interplay between intellectual property rights and health needs of the population. The Indian pharmaceutical industry is a special scenario of an overlap between patent regulation and healthcare objectives, which has resulted in a trade-off between innovation and affordability. This paper examines the evolution of pharmaceutical patent law in India and its impact on the growth of the generic drug industry. By integrating legal analysis with pharmaceutic indicators such as drug pricing, bioequivalence, and manufacturing practices, the study evaluates how legal provisions influence both innovation and access to medicines.

The paper focuses on how the transition of the Indian process patent system into a product patent system (as part of the TRIPS Agreement) has affected the structure and functioning of the pharmaceutical industry. It also highlights the role of legal protection systems such as Section 3(d) and required licensing and patent opposition systems that have assisted in the reduction of monopolistic activities and the affordability and access of necessary medicines by all.

Keywords: Patent Law, Generic Drugs, Pharmaceutical Regulation, Drug Accessibility, Innovation Policy, India

How to cite this article: Das H, Sardar AK, Ojha B, Das B, Deuri H, Pathak K. Patent Law And Generic Drug Industry In India: Legal Perspectives On Accessibility And Innovation. Int J Drug Deliv Technol. 2026;16(4):769-781. DOI: 10.25258/ijddt.16.4.92

Introduction

The interface of patent law and the Indian pharmaceutical industry is one of the most crucial aspects of law and policy, economic development, and health care. India as a country with a good reputation of being the pharmacy of the developing world has played a key role in supplying cheap generic drugs to the domestic and foreign market. This peculiarity is also strongly affected by the patent regime that was altered numerous times throughout its evolution under the impact of the international demands and the needs that the domestic healthcare has. The Indian patent regime and, more particularly, when it was reformed in the wake of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement in 2005 was a radical shift towards a product-based regime as opposed to the process-based regime. This transformation has been endemic in regards to innovation, competition and access of medicine.

The Indian patent system In India, the system of process patent was designed according to the Patents Act of 1970 that allowed pharmaceutical companies to create drugs in other forms without infringing on the patent claims. This has enabled a vigorous growth of a robust generic drug industry that has made drug more affordable and accessible to most individuals (Gomase et al., 2025). This has been applied to reverse-engineer patented medicines by Indian pharmaceutical companies, and develop cheap replacements, which served to address fundamental health issues in the population. This however changed with introduction of product patents with TRIPS which granted exclusive rights to the patent holders of the end-product

drug in the pharmaceutical industry which boosted safeguarding of intellectual property and resulted in the dread of monopolies and higher prices of drugs.

In order to overcome these challenges, India came up with some legal safeguards on its patent regime to create a balance between incentives to innovate and the interests of the population health. Remarkably, one of the laws that is relevant in deterring the practice of evergreening is the Indian Patents Act, 1990, Section 3(d), which provides that in instances where slight changes are made in the existing drugs to enhance the period of the patent term, it will not be considered as evergreening (Singh et al., 2022). Section 3(d) puts stringent requirements on patentability so that only real innovations are granted protection. There are also other requirements such as compulsory licensing which provides the government the right to license the production of the patented drugs without the consent of the patent holder under some circumstances such as an epidemic among the population or unreasonable pricing. The system of patent opposition also promotes transparency and accountability by enabling third parties to oppose weak or unreasonable patent claims.

This dynamic nature has been created by the interaction between these legal processes and pharmaceutical industry, whereby the delicate balance between innovation and accessibility has been created. Although the increase in patent protection is supposed to promote research and development investments, it also serves to limit access to the much needed medicines especially among low- and middle-income groups (Patel et al., 2024). Conversely, a strong generic industry will make it affordable, but may result in further doubts over the lack of innovation motivation. Such duality makes India an interesting case study to examine how both economic and social purposes of the legal structures can be adapted.

The paper, therefore, talks about the history of the patent law in India, and its impact on the generic drug market in respect to the accessibility and innovation (Kumar et al., 2024). Using a mix of legal analysis, pharmaceutical and economic considerations, the paper aims at providing a general understanding of how the patent regime currently functions in India to decide on the availability, affordability and development of medicines in a globalized environment.

Evolution of Patent Law in India

The development of the law of patent in India is a process of a slow and planned shift based on the socio-economic interests of the country, the needs of populations in the field of health, and the requirements of international law (Ali et al., 2024). Since the colonial past to the present internationally acceptable intellectual property laws, the patent system in India has been changing drastically especially in the pharmaceutical industry where the trade-off between innovation and accessibility has been at the heart of the matter.

During the pre-independence era, India had a patent system that was under the Indian Patents and Design Act, 1911 which was to a great extent based on the British law. This system offered good product patent rights, even in the case of pharmaceuticals, and thus gave wide monopoly rights to the foreign corporations. This led to the high cost of drugs and little domestic production of drugs. The system was not able to fulfill the health care demands of the Indian population that is why there were general concerns on affordability and access to necessary medicines.

After independence, the Indian government realized the importance of reforming the patent system in the support of the local industry and health. This resulted in the adoption of the Patents Act, 1970, a milestone law that radically transformed the pharmaceutical scene. The Act repealed product patents on food, chemicals and pharmaceuticals in favor of process patents that have a reduced term (Dash et al., 2023). This enabled Indian companies to legally manufacture generic versions of patented drugs using alternative processes. This resulted in the Indian pharmaceutical industry developing at a high rate, becoming one of the leading companies in the world in the production of generic drugs. Drugs were much cheaper and healthcare availability was increased nationwide.

Yet, this regime became pressured more in the age of globalization. As India joined the World Trade Organization (WTO) in 1995, it had to adhere to the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement which required the implementation of product patents in all areas of technology, pharmaceuticals included. India modified its patent law in three stages, 1999, 2002 and 2005 to comply with the TRIPS.

The Patents (Amendment) Act, 1999 has added the so-called mailbox provision and Exclusive Marketing Rights (EMRs), which means that pharmaceutical product patent applications can be filed prior to full compliance (Rao et al., 2025). The 2002 amendment reinforced the patent regime by increasing the patent term to 20 years and the definitions and procedural matters. The most notable change was the Patents (Amendment) Act, 2005 that reintroduced product patents on pharmaceuticals and chemicals, a significant departure of the previous process-based system.

Although it shifted to a product patent regime, India had vital protections to safeguard the health of people. Section 3(d) was added to discourage evergreening by ensuring that only improvements in the therapeutic activity of known substances can be patented under the section 3(d). Also, clauses of compulsory licensing were not abandoned but reinforced so that the government could licensed generic production of the patented drugs on certain conditions like high prices or insufficiency (Singh et al., 2025). The pre-grant and post-grant opposition procedures also provided

transparency and gave the stakeholders a chance to provide action against unreasonable patents.

India has been able to balance its patent regime to favour innovation as well as access to medicines in the post-TRIPS era. Although multinational corporations are enjoying better protection in their intellectual property, domestic pharmaceutical firms are still able to survive by producing generic drugs and exporting them (Shukla et al., 2026). The development of the patent law in India can therefore be seen as a balanced strategy that balances both international requirements and domestic healthcare needs, which makes it an exemplary case to other developing countries.

Figure 1: Timeline of Patent Law Evolution in India

Legal Framework Governing Pharmaceutical Patents

In India, the legal system under pharmaceutical patents is mainly organized in accordance with the Patents Act, 1970, which has been amended to adjust to the international requirements of the TRIPS Agreement. This structure is a balanced way of protecting intellectual property rights and availing affordable medicines to the citizens (Gomase et al., 2025). In contrast to most developed jurisdictions which focus on a robust patent system, Indian law has a number of public-interest protections in place to check the abuse of patent rights, especially in the pharmaceutical industry.

One such provision that is of immense significance in this context and is the provision that would play a crucial role in preventing the occurrence of evergreening is Section 3(d) of the Patents Act. Evergreening is a process that is used by pharmaceutical companies to prolong the life of a patent by making slight changes to an already existing drug without any meaningful change in terms of its therapeutic value. Section 3(d) specifically restricts the patentability of the novel forms, derivatives or variations of the familiar material unless they can demonstrate significant benefit to the treatment outcome (Singh et al., 2022). The reason is that the actual innovations will only be able to enjoy protection of patent and hence preventing the artificial extension of monopolies. This decision was bolstered by the Supreme Court ruling that invalidated a patent claim on a modified cancer drug in the Novartis case (2013) that stated that the modified drug failed the enhanced efficacy test. Section 3(d) can thus be successfully utilized in stimulating substantive innovation whilst safeguarding the interests of the population with regards to health.

Compulsory licensing is another important process in the Indian system of patenting, and is regulated by Section 84 of the Patents Act. Compulsory licensing is the government or any third party that is allowed by certain conditions to manufacture a patented pharmaceutical product without the permission of the patent holder. These are the situations where the patented drug is not provided to the people at a fairly affordable price, poorly done or the drug is not being developed in the Indian territory (Patel et al., 2024). This is done as a corrective action to prevent the abuse of the patent rights particularly in a case where life saving drugs are sold at a price that the masses cannot afford. An example of this is the granting of compulsory license to Natco Pharma to manufacture a generic of the Nexavar drug of cancer invented by Bayer making the treatment much more affordable. Compulsory licensing is not only yielding more access to the needed medicine but also allows competition to emerge onto the market of pharmaceuticals, which leads to lowering the prices (Gupta and Raza, 2023).

Besides these provisions, the Indian patent regime has strong pre-grant and post-grant opposition mechanisms, which also play a large role in ensuring the quality and integrity of patents granted. Pre-grant opposition gives a chance to any individual to oppose a patent application prior to its grant on the basis of novelty, obviousness or other reasons like failure to comply with the requirements of Section 3(d) (Kumar et al., 2024). This will promote transparency and enable the civil society groups, generic pharmaceutical companies, and health lobby groups to participate in the process of patent review. It is a filtering mechanism to filter weak or frivolous patent applications at an early stage of the process.

Similarly, the post-grant opposition system provides the parties that might have an interest in opposing a patent within one year after granting. This can be used as a

corrective measure to review the soundness of a patent on substantive grounds. All these antitrust actions form a more responsible attitude towards the patent system and reduce the possibility of unjustified monopolies. They also help in minimizing the protracted litigation process as the disputes are solved before and therefore the legal process will be more efficient.

Moreover, Indian legal system focuses on the concept that patents are not a right but are under a wider social and economic consideration. The system integrates the interests of the populace in the management of patents in such a way that potentially protection of intellectual property should not be at the cost of accessibility (Ali et al., 2024). This is particularly required in a developing country like India where a high percentage of the population lives on generic medicines which are cheap.

All in all, the Indian legal framework of pharmaceutical patents is a well-balanced and practical system which balances incentives of innovation with the needs of the community health. India has developed a paradigm of not only discouraging monopolies but also establishing a competitive and affordable pharmaceutical market with such mechanisms as compulsory licensing, opposition, and Section 3(d) among others (Dash et al., 2023). The framework is still an important point of reference to other emerging nations, who are attempting to strike a balance between protecting intellectual property and the demand to obtain affordable healthcare.

Table 1: Key Legal Provisions in Indian Pharmaceutical Patent Law

Provision	Description	Impact
Section 3(d)	Restricts evergreening	Promotes genuine innovation
Section 84	Compulsory licensing	Improves access
Pre-grant opposition	Patent scrutiny	Prevents weak patents
Post-grant opposition	Validity review	Enhances accountability

Generic Drug Industry in India

The generic pharmaceutical business in India is among the most important pillars of the healthcare system of the country and the pharmaceutical supply system of the world. India is commonly known to be among the largest producers and exporters of generic medicines worldwide, commonly referred to as the pharmacy of the developing world. This image is based on the fact that the country is capable of manufacturing high quality medicines at significantly reduced prices, thus enhancing the availability of much needed treatment both in the domestic and international market (Rao et al., 2025). This industry is also strongly associated with the patent regime in India, especially the focus on process patents that existed in India before 2005 which allowed domestic companies to engage in reverse-engineering patented drugs and produce cheaper substitutes.

Generic drugs are simply pharmaceutical products, which are bioequivalent to their brand counterparts, i.e., share the same active ingredients, dosage form, strength, route of administration, and therapeutic effect. Regulatory bodies demand that generic drugs possess similar bioavailability and efficacy, so that patients will be provided with the same clinical advantages as branded drugs. According to Reddy et al. (2022), this equivalence assures that cost savings will not be at the cost of quality, safety, or even effectiveness (Singh et al., 2025). Regulatory control by agencies like the Central Drugs Standard Control Organization (CDSCO) in India provides that generic drugs are of high quality, and at times, these standards relate to international standards, including WHO-GMP and USFDA guidelines.

Cost efficiency is one of the differentiating factors of the Indian generic pharmaceutical industry. Indian manufacturers enjoy relatively low production costs because of economies of scale, raw materials availability and low labor costs as compared to developed countries. Also, a well-qualified workforce, scientists, chemists and engineers among them make the processes of drug development and manufacturing efficient (Shukla et al., 2026). This technical know-how and low cost enables the Indian business to manufacture drugs at a small fraction of the price of their branded counterparts and healthcare becomes cheaper to millions of individuals.

The other important aspect that favors the development of the generic drug industry in India is the good legal and policy environment. As explained above, the timely introduction of generic drugs into the market through provisions like Section 3(d), compulsory licensing and patent opposition mechanisms have avoided needless extensions of patents and monopolizing activities. This law system promotes competition, thereby reducing prices and enhancing supply (Bhattacharyya et al., 2024). In addition, the government efforts and policies of encouraging domestic production, including the Make in India campaign and production-linked incentive (PLI) schemes have also contributed to increasing the global competitiveness of the industry.

The generic pharmaceutical industry in India also makes a significant contribution to the world population health especially in the low- and middle-income nations. The Indian pharmaceutical firms are a significant provider of life saving medication that are used in the treatment of

diseases like HIV/AIDS, tuberculosis, malaria, and other chronic diseases. An example is that major percentage of antiretroviral drugs in the global HIV treatment programs is imported by Indian manufacturers (Devi et al., 2022). This donation has played a significant role in saving lives and enhancing the health status in areas with limited resources. Indian generics have been cheap and have the high production capacity to allow international agencies, including the World Health Organization (WHO) and UNICEF, to roll out extensive treatment programs.

Besides providing ready-to-use formulations, India is also a major manufacturer of active pharmaceutical ingredients (APIs), the basic elements in the manufacture of drugs. This vertical integration will strengthen the strength and independence of the pharmaceutical industry, making it less reliant on imported goods and guaranteeing a consistent supply chain (Gupta et al., 2023). Nevertheless, issues of API imports especially in countries such as China have also been experienced in the industry and this indicates that the policy still requires reinforcement to enhance production in the country.

Although the Indian generic drug industry has its merits, it does not pass without challenges. There is continuing concern regarding increasing regulation by international markets, and pricing pressures, and competition by the other emerging economies (Gupta et al., 2023). Moreover, the shift to a product patent system following the compliance with the TRIPS has obliged the Indian companies to change their business models with more focus on innovation, biosimilars, and sophisticated generics. The industry has however proved resilient through research and development, expansion into regulated markets and high standards in the manufacturing process.

To sum up, the generic drug market in India is a pillar of affordable health care, both nationally and internationally (Tenni et al., 2023). It has been successful due to its low cost production, highly qualified human resource, favourable legal frameworks and robust regulatory systems. India has remained a critical resource to solving global health problems especially in the developing nations by providing quality, cheap medicines. With the changing pharmaceutical environment, the Indian generic industry is in a good position to maintain its position and slowly transition to a more innovative and technologically advanced industry.

Research Methodology

Research Design

The current research takes a qualitative and analytical research design to analyse the association between patent law and generic pharmaceutical industry in India. It is mainly founded on a doctrinal research method of law, or, put differently, a method of legal research that is systematic, that is, an analysis of statutory provisions, legal principles and policy frameworks of intellectual property rights in the pharmaceutical industry (Bhattacharyya et al., 2024). Moreover, the research involves a descriptive and evaluative viewpoint to comprehend the impact of these legal provisions on medicines accessibility and outcome of innovations, in the Indian scenario.

Sources of Data

The study has been founded on primary and secondary data sources. The main sources are statutory enactments, i.e., the Patents Act of 1970 and its subsequent amendments, and international legal documents, i.e. the TRIPS Agreement. Court decisions and case laws on pharmaceutical patents are also a key component of the primary data. The Secondary sources are scholarly materials, such as books, journal articles, research papers, and legal commentaries (Devi et al., 2022). The study is also supported by reports by national and international bodies, policy documents and analysis of the pharmaceutical industry.

Method of Data Collection

The information to be used in this study has been gathered both in libraries and online research. Online legal databases, academic repositories and government websites have been accessed to obtain relevant materials. The research is conducted with the close choice and screening of authoritative and credible sources to guarantee accuracy and reliability of the analysis. The data obtained is then systematized to enable meaningful interpretation.

Analytical Framework

The research uses thematic and interpretative analytical approach to analyze the issues of high concern in terms of patent law and generic drug industry. It is concerned with how a shift to a product patent regime can be made in compliance with TRIPS and what the consequences of such a shift are on innovation and access to medicines (Gupta et al., 2023). The law protective measures, particularly Section 3(d), forced licensing, and opposition to patents, are specifically considered and their effect in the prevention of monopolistic practices and facilitation of the public health is examined. The framework also takes into account pharmaceutical indicators, including drug pricing, bioequivalence, and manufacturing standards to offer a multidimensional perspective on the topic.

Scope of the Study

The study is limited to the Indian patent law system and its effect on the pharmaceutical industry, especially the generic drug industry. It highlights the progress in the post-TRIPS age particularly following the amendment of 2005 that added product patents (Reddy et al., 2022). The research is based on legal and policy facets instead of experimental or clinical levels of drugs, which seek to comprehend the influence of law on accessibility and innovation.

Limitations of the Study

The research is constrained by the use of doctrinal and secondary data, which might not be a complete representation of dynamic industry processes and the views of stakeholders. It lacks empirical fieldwork and thus limits the inclusion of primary information of industry participants or policymakers (Abbas et al., 2023). Also, the fact that the global intellectual property regimes and pharmaceutical innovations change rather fast can have an effect on the relevance of the findings in the long run.



Figure 2: Structure of Generic Drug Manufacturing Process

RESULTS and DISCUSSION

The results of the present study reveal that the patent law regime in India has played a significant role in enhancing availability of drugs in India and moderated level of pharmaceutical research. By integrating both legal and drug standards, India has come up with a strategy that assists in addressing the health interests of both the people and industrialization. The results show that legal provisions like Section 3(d), compulsory licensing, and patent opposition mechanisms have had a direct impact on drug pricing, competition in the market, and the quality of generic medicines (Abbas, 2024). Simultaneously, the pharmaceutic analysis proves that generic medicaments manufactured in India are on the same level with conventional medicaments in terms of their safety and effectiveness.

Drug Pricing and Accessibility

The major impact of the analysis is the immense decrease in the price of the drugs because of the popularity of generic medicines. The statistics clearly show that generic drug is relatively cheaper than their patented versions, a fact which has resulted into better accessibility to treatment in a number of therapeutic classes. This price difference is particularly necessary in such a nation like India where large part of the population relies on the low cost of healthcare resolutions.

Table 2: Comparative Drug Pricing Analysis

Drug Category	Patented Drug (INR/month)	Generic Drug (INR/month)	Reduction (%)
Oncology	120,000	8,500	92.9%
HIV/AIDS	15,000	1,200	92.0%
Cardiovascular	3,500	600	82.8%
Antibiotics	1,200	250	79.1%

This table indicates that the reduction in prices will be between approximately 79 and over 92 percent depending on the groups of drugs (Siwal, 2022). The biggest reductions are observed in life saving drugs such as oncology and HIV/AIDS drugs, where price plays a significant role in saving lives of patients. These results imply that the Indian patent system, with its legal protection, has made possible the manufacture and sale of cheap substitutes without affecting the therapeutic efficacy.

The use of legal tools like compulsory licensing has played a key role in this regard. The government has ensured that such crucial medicines are not beyond reach by allowing the generic drug manufacturers to produce patented drugs in some conditions. Similarly, the patent opposition processes avenue offers an avenue of preventing unnecessary patent monopolies in the market thereby ensuring that generic drugs are introduced in the market at the right time.

Impact on Innovation

Although the situation has become much more accessible, the effect of the patent law in India on innovation is a bit more complex. These findings indicate that Section 3(d) has been effective in restricting the incremental innovations which do not contribute substantially to the therapeutic benefits (Ilin and Lazanyuk, 2024). This has discouraged the evergreening where minor changes are made in an effort to extend the protection period of the patent yet no meaningful development is made.

In the meantime, this restrictions of weak patents has encouraged pharmaceutical companies to focus on actual innovation. Firms are currently investing in the development of new chemical molecules, biosimilars and advanced drug delivery devices. This is a pointer of a shift towards non-cosmetic changes to more material research and development processes.

It is observed though that the patent regime in India is also considered to be limiting to multinational pharmaceutical companies particularly with regard to incremental innovation. This has created an apprehension about the decrease in foreign investment into some sectors of pharmaceutical research (Krishna et al., 2022). However, overall, there is a trend towards a much more significant and socially relevant form of innovation in the Indian system.

Legal Mechanisms and Market Competition

The study also reveals that legal requirements and judicial influence have also boosted competition within the pharmaceutical industry. Having a strong generic drug industry has greatly diminished the monopolistic activities resulting in more competitive price as well as better access to medicines.

Table 3: Legal Impact on Market Dynamics

Mechanism	Effect	Outcome
Section 3(d)	Limits weak patents	Increased generic entry
Compulsory licensing	Enables production	Lower drug prices
Judicial rulings	Clarify law	Balanced competition
Patent opposition	Filters patents	Reduced litigation

The table points out the role played by various legal mechanisms in the development of market dynamics. The reason to do section 3(d) is to ensure that only really innovative drugs are patented and generic competitors can enter the market (Ravi et al., 2023). Compulsory licensing is a remedial measure, which must be implemented in case of inaccessibility or unaffordability of patented drugs.

Court decisions also have been vital in interpretation of patent laws and precedents that are used to guide future cases. This kind of ruling is precise and coherent and so it is imperative in a stable legal environment. Secondly, the patent opposition procedures may be employed as an effective tool of killing bad patents early in its life and this will reduce the likelihood of engaging in a protracted legal battle.

In sum, all these legal instruments are everything that constitutes a competitive pharmaceutical market, which is both consumer- and producer-friendly.

Pharmaceutic Evaluation

Pharmaceutically, the study greatly confirms that generic drugs produced in India uphold high standards of quality, safety, and effectiveness, and can therefore be trusted as substitutes to branded medicines (Kumar and Sahai, 2022). Such an equivalence is not presumed but rather scientifically proven by conducting a number of rigorous regulatory and clinical tests. This validation process is based on bioequivalence testing that makes sure that generic drugs behave similarly to their branded counterparts in the human body. These tests also assess key pharmacokinetic values, including absorption, distribution, metabolism, and excretion (ADME), and thus ensure that the generic formulation provides the same therapeutic effect.

Bioequivalence is a study that is intended to compare the absorption rate and extent of absorption of a drug between a generic product and reference branded drug. The regulatory agencies normally insist that the maximum concentration (Cmax) and area under the curve (AUC) of the generic drug should be within a reasonable limit (usually 80-125) of the branded drug. This statistical equivalence makes the generic drug enter the bloodstream at a rate and to the same degree, thus, making it have the same clinical effect. Consequently, patients will be able to use branded and generic medicines without any serious alterations in therapeutic results. Such scientific rigor does not leave any doubts about the effectiveness of generic medications, and strengthens their persuasiveness in the national and international markets.

Table 4: Bioequivalence Comparison

Parameter	Branded Drug	Generic Drug
Bioavailability	High	Equivalent
Safety Profile	Established	Comparable
Efficacy	Proven	Equivalent
Regulatory Approval	Required	Required

The generic drugs as shown are equal to the branded drugs in all the necessary parameters. The bioavailability equivalence demonstrates that the drug will achieve the same systemic circulation concentration and similar safety profiles demonstrate that adverse effects and risk-levels are the same. Equivalent efficacy, in a similar manner, proves that the beneficial effect of the therapy, be it curative, preventive or symptomatic, is retained. Notably, generic and branded drugs have to go through the regulatory approval, which means that no drug will end up on the market having failed to meet the set quality standards.

Other than bioequivalence, the safety and effectiveness of generic drugs are further confirmed due to stringent regulatory controls. Central Drugs Standard Control Organization (CDSCO) in India is the key body in the assessment and approval of pharmaceutical products. Approval of a drug depends on the submission of all information, as far as formulation, stability, pharmacokinetics and manufacturing processes are concerned. Also, post-marketing surveillance systems track adverse drug reactions, which constantly evaluate safety even after the drug has been released into the market. This multi-layered regulatory system will enhance the safety and efficacy of generic drugs during their lifecycle.

Compliance with global standards of manufacturing is another major critical factor that has led to high quality of Indian generic medicines. Indian pharmaceutical firms adhere to internationally accepted standards, including World Health Organization -Good Manufacturing Practices (WHO-GMP) and United States Food and Drug Administration (USFDA) (Kumutha et al., 2022). These guidelines apply to all drug manufacturing processes such as the sourcing of raw materials, manufacturing process, quality assurance, packaging and storage. Such stringent standards provide conformity, purity, and reliability of pharmaceutical products.

These global standards have been adopted, and this has helped Indian pharmaceutical firms to be among the largest exporters to regulated markets like the United States, Europe and other developed regions. Indeed, India has one of the largest quantities of USFDA approved manufacturing plants outside the United States. The fact that this has been accepted all over the world is a good testimony of the quality and reliability of the Indian generic drugs. It is also adding credibility to the Indian pharmaceutical sector as a whole making it a reliable supplier of the global healthcare ecosystem.

Besides compliance with regulations and the quality of manufacturing, the development of formulation technologies also enhanced the performance of generic medicines. The advanced pharmaceutical research has made it possible to develop advanced drug delivery systems which include sustained-release (SR), controlled-release (CR), and extended-release (ER) compounds. The technologies enable drugs to be delivered slowly over time, enhancing treatment efficacy and patient adherence. As an example, sustained-release preparations lessen the dosing schedule that is especially helpful with chronic disease like high blood pressure or diabetes.

Moreover, novel methods of delivering drugs have also contributed to the bioavailability of generic drugs and accuracy, such as nanotechnology-driven carriers, liposomal formulations, and targeted delivery systems. Such developments guarantee a better delivery of the drug to the targeted site of action reducing to the minimum side effects and maximizing treatment effects. Indian pharmaceutical firms are also putting more investments in such technologies to manufacture high-value generics and complicated formulations to satisfy the international standards.

Stability and shelf-life are another quality aspect of pharmaceuticals. The generic drugs are subjected to strict stability testing in different environmental conditions, to ascertain that the drugs maintain their potency, safety, and efficacy during their shelf life. This is especially relevant in the countries that have varied climatic conditions such as India where temperature and humidity have the potential of influencing the drug stability. International stability standards help to realize that generic medicines become effective even in the harsh conditions of storage.

The importance of quality control systems and quality assurance systems cannot be ignored in this scenario. The Indian pharmaceutical industries have enforced quality assurance at all production phases, such as testing of the in-process and the finished product. High-quality tests like high-performance liquid chromatography (HPLC), mass spectrometry, and dissolution testing are employed to ascertain that every lot corresponds to specifications set out. This careful method reduces the variability and ensures uniformity in the production batches.

In spite of these advantages, it should be noted that high standards of pharmaceuticals have to be enhanced and controlled constantly. Regulatory agencies should be on the lookout to curb cases like low quality or fake drugs, which may compromise the people. The credibility of generic medicines should be maintained through the strengthening of the pharmacovigilance systems, increasing the regulatory capacity and providing transparency of the manufacturing practices.

In summary, generic drugs in India undergo pharmaceutical assessment that indicates that generic drugs are therapeutically equivalent, safe and of good quality similar to branded drugs. With its stringent bioequivalence testing, stringent regulation, compliance with world manufacturing standards, and ongoing technological advancement, Indian generic drugs have gained recognition as a reliable and effective health remedy. They are necessary in both national and international health systems since they can provide the same clinical outcomes at a much lower cost. With the pharmaceutical industry constantly changing, the determination by India to ensure that it upholds a high standard of quality and efficacy will be essential in strengthening its stand as a world leader in the production of generic drugs.

Judicial Interpretations

The interpretation and enforcement of the pharmaceutical patent law in India has been facilitated by the ruling of the courts. The judiciary has been the balancing force, the intellectual property right is exercised and on the other, the

health of the people and access to medicines are preserved. The Indian courts have given a clear picture on many important provisions; such as Section 3(d), compulsory licensing and the standards of patentability in a series of historic cases. Such choices have contributed greatly to the law and the operation of the pharmaceutical industry.

F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (2008–2015)

The dispute between Roche and Cipla was that of the lung cancer drug Erlotinib that was patented and was sold as Tarceva. Cipla had released a generic product at a considerably cheaper cost which Roche had sued. The Delhi High Court gave Cipla the go-ahead to manufacture and market the generic drug pending the case, which, the court also said, stressed the issue of affordability and the interest of the people.

This case brought to the fore the judicial treatment in weighing patent rights and access to affordable healthcare. It recognized the importance of life saving medicines being affordable to those in need and enhanced the role of generic manufacturers towards achieving this objective.

6.5.2 Bayer Corporation v. Natco Pharma Ltd. (2012)

India In Bayer Corporation v. Natco Pharma Ltd., India it awarded its first compulsory license in Section 84 of the Patents Act. Natco Pharma was permitted to produce a generic of a patented cancer drug, Nexavar (Sorafenib Tosylate), by Bayers. This decision was made with the understanding that the drug was not offered at a fairly affordable price and that there was an inadequate supply of the drug and that the patent was not sufficiently worked in India.

The case changed significantly the access to medicines as it resulted in a significant drop in the cost of treatment. It also depicted how mandatory licensing may be utilized in real practice as a tool of the law to address the concerns of the well-being of the populace. The decision solidified the fact that patent rights are not absolute and they should be exercised in a way that is in line with the interest of the population.

Novartis AG v. Union of India (2013)

Novartis AG v. Union of India case is one of the most significant cases in Indian patent law. Novartis patented a modified version of the cancer drug Imatinib Mesylate, which is marketed as Glivec. The Supreme Court refused the application of the patent on the basis that the altered version failed to show better therapeutic efficacy as was required under Section 3(d) of the Patents Act. The Court decided that when physico-chemical properties are improved, but no substantial clinical advantage results, the improvements are not patentable inventions.

This decision brought together the shrinking of the Section 3(d) and practically blocked the evergreening mechanism of pharmaceutical firms seeking to extend their patent life by making minor modifications. It ensured the future of generic substitutes to life-saving medicines that were cheap and established a high standard of patentability in India.

Merck Sharp & Dohme Corp. v. Glenmark Pharmaceuticals (2015)

Merck Sharp and Dohme Corp. v. Glenmark Pharmaceuticals was a case of the anti-diabetes drug, Sitagliptin. The Delhi High Court passed a temporary injunction against Glennark, thus, banning the production of the generic version of the drug. The Court ruled that Merck had proven a prima facie case of patent infringement as well as the validity of the patent.

This decision meant that Indian courts are also highly protective of valid patents. It strengthened the notion that, although public health is crucial, the legitimate intellectual property rights should not be violated as well. The ruling is based on judicial neutrality and willingness to favor innovation in the case in case the legal circumstances are met.

Bristol-Myers Squibb v. BDR Pharmaceuticals (2020)

This is whereby BDR Pharmaceuticals wanted a compulsory license to manufacture Bristol-Myers Squibb-patented cancer drug Dasatinib. This was rejected on the basis of procedural defects, in particular the lack of adequate attempts to obtain a voluntary license prior to seeking compulsory licensing. The move made it clear that compulsory licensing is not a right of its own and that it has to be applied in complete adherence to the statutory provisions. It strengthened the ethical standards of the processes in the patent system and ensured that the mechanism is exercised at its discretion and implemented in the actual cases of social need.

Overall Judicial Impact

The overall effect of these court rulings has been tremendous in developing the pharmaceutical patent environment in India. The courts have always been very stringent on their requirements of patentability particularly in Section 3(d) and it has ensured that it is only the real and substantial innovations that could be patented. Simultaneously, judiciary has embraced systems like compulsory licensing as a way of enhancing access to vital medicines.

Such resolutions have helped to create a level playing field in which innovation and the accessibility are accorded the necessary attention. The courts have been very critical in ensuring that patent right is not abused at the expense of promoting research and development. It has thus emerged as a pillar of Indian patent system supporting legislative

provisions and strengthening the overall system of treatment of pharmaceutical patents.

Comprehensive View

The general understanding of the work, which consists in the synthesis of legal and pharmaceutic approaches, is that India has created a very balanced and operationally efficient system that is at the same time conducive to the availability of medicines and to innovation. This balance is not accidental or given but the result of the purposeful creation of law, policy change and institutional control which have evolved over decades in response to domestic medical need and to the needs of the international market of intellectual property (Parthasarthi et al., 2022). The Indian patent regime particularly in light of the TRIPS-based amendments of 2005, is a good case study of how a developing country could be capable of strategically aligning the global best standards with the local priorities of health.

The very essence of this balance is that the Indian patent system should be able to avoid the misuse of the intellectual property rights and yet leave room to actual innovation. India has a framework in place unlike other regimes which provide broad monopoly rights without adequate examination, its framework includes certain provisions that provide that only meaningful and substantive inventions can be granted a patent (Singh et al., 2023). The provisions like Section 3(d) are a filter that cannot be overlooked and makes pharmaceutical companies unable to prolong the patent monopoly by using non-therapeutic, but minor changes. It will further ensure that the patent system is not rent-seeking and will be fulfilling the role of the patent system which is to encourage actual innovation. By restricting evergreening, the law will allow earlier generic drugs to enter the market, and therefore, raise competition and drug prices.

In addition to this is the system of compulsory licensing which is a remedial and just system in the patent system (Sharma et al., 2024). It strengthens the notion that patent rights are not eternal and must be used in a way that is in line with the interest of the people. Compulsory licensing can be used when there is no affordability of or inadequate supply of life-saving drugs that the patent holder has not granted permission to manufacture a generic form of the drug. This is one of the mechanisms that will ensure that high prices and low supply will not pose a threat to the availability of the required medicines. A combination of these provisions within the law has a system that does not encourage monopolistic practices but encourages research and development in the pharmaceutical fields.

Pharmacologically, this legal framework is even more effective because the cost of affordability is not compromised in the quality, safety or efficacy. Bioequivalence, adherence to the international standards of production and long-term quality control regulatory procedures will ensure that generic drugs produced in India are therapeutically the same as their brand counterparts. According to Abbas (2024), this two-fold focus on legal protection and pharmaceutical rigour forms a framework in which accessibility and quality do not contradict but are synonymous. The concept of cost reduction does not always imply the decline of the standards as the emergence of generics of high quality at significantly lower prices demonstrates.

The interplay between the drug and the pharmaceutical practice is also one of the factors which have contributed to creation of a robust and competitive generic drug industry. Indian patent regime promotes a vibrant market atmosphere by enabling generic drug to enter the market when it is due and offer healthy competition (Beerannavar et al., 2025). This type of competition not only assists in price reduction, but also efficiency and innovation among the domestic pharmaceutical firms. Investment in more complex drug formulations, biosimilars and complex generics is also increasing by the firms and appears to be a shift towards value-added innovation as opposed to replication. Hence, the system facilitates the short and long-term growth of industries and national health, respectively.

However, it would not be a complete interpretation process until it would indicate the issues and limitations of the existing system. Some of the chief concerns are the relatively low investment in premium research in pharmaceuticals, in the creation of new chemical species and breakthrough therapy (Ali et al., 2023). Though the restrictive interpretation of patentability in Section 3(d) can be very effective in curbing evergreening, it can also have the inadvertent effect of discouraging certain forms of incremental innovation that may have clinical applications. Additionally, the multinational drug companies are more likely to perceive the Indian patent system to be negative and this may impact the foreign direct investment and technology transfer.

The other emerging challenge is the fast changing science of pharmaceuticals, especially with the emergence of biologics, gene therapies and personalized medicine. These advanced spheres of therapy are connected with advanced research and introduce new problems to the patentability, regulation process and the bi-equivalence requirements. The current legal framework, which much of its designing was based on small-molecule drugs, might need to be further refined to be able to meet these new developments (Chakraborty et al., 2025). The system needs to be made flexible and progressive to be in a position to keep up with its relevance in the future.

Despite these challenges, overall findings of the study indicate that the Indian model remains a system of a public health-driven patent system that is not necessarily designed to promote fair access at the cost of innovation (Abbas et al., 2024). The legal and pharmaceutical standards interrelation constitute a comprehensive framework of many facets of healthcare ecosystem. It guarantees the

supply of the needed medicines to a vast population and the quality and consistency of pharmaceutical products.

It is interesting to note that the Indian experience can be applied to other developing economies undergoing similar dilemmas on how to safeguard intellectual property and at the same time address the health needs of the people. The problem of international agreements and domestic healthcare priorities is a conflicting issue in most countries, in the majority of cases, it is either excessive protection of patents or a lack of appropriate incentives to innovate. The design of a flexible and context-sensitive patent regime exhibited by India shows that it can be possible to achieve both goals (Siwal et al., 2022). By providing protection in the form of high standards of patentability, compulsory licensing and opposition systems, countries can establish a system that is not abusive but one which will promote real scientific progress.

In addition, the Indian model emphasizes the significance of institutional capacity and enforcement of regulations. The laws can never work without practical enforcement and supervision. The availability of regulatory bodies, courts and policy making institutions in facilitating the interpretation and enforcement of the patent laws is crucial in that there is a check and balance of conflicting interests (Ilin et al., 2024). Open communication, involvement of stakeholders and making decisions based on evidence also add to the effectiveness and credibility of the system.

To sum up, the legal and pharmaceutic analysis shows a clear and evident indication that India has gone a long way towards attaining a sustainable balance between the accessibility and innovation in the pharmaceutical industry (Krishna et al., 2022). Although some issues still exist, especially regarding the enhanced research of drugs and the global demands towards enhanced intellectual property protection, the system as a whole achieves the goal of promoting the health of the population, without completely deterring innovation. The Indian patent system is an exemplary system of patenting that is pragmatic and adaptive and can be examined and possibly be replicated by other developing countries. By further refining its policies and enhancing its regulatory framework, India can be further shaped into a global pioneer in generic drugs production, as well as a potential pharmaceutical hub.

Challenges and Future Directions

Although the patent law system in India has had remarkable success in its endeavors to strike the right balance between accessibility and innovation, a number of emerging issues still pose challenges to the effectiveness of its operations in the rapidly changing pharmaceutical system. Some of the key issues include increased complexity of contemporary therapeutics particularly in the area of biologics, biosimilars and personalized medicine. In addition to being produced based on living organisms, biologics require highly complicated production processes as compared to small-molecule drugs, which are conventionally produced using a chemical synthesis procedure (Ali and Sinha, 2024). This sophistication raises key issues of patentability, regulatory paths and bioequivalence criterion. The current legal system that was mostly geared towards traditional pharmaceuticals might need some change to suitably accommodate these new advanced types of therapies.

The other urgent issue is the pressure of the world to enhance intellectual property protection. Promotion Multinational pharmaceutical companies and the developed nations are more likely to suggest more restrictive patent regimes, which include longer terms of the patents, data exclusivity, and reduced dependence on compulsory licensing. These are the pressures used in bilateral trade agreement and international negotiations (Dash et al., 2023). Even though enhanced intellectual property protection will encourage foreign investment and innovation will also have the possibility of limiting access to inexpensive medicines in India and other developing countries. Therefore, policymakers must create a fine balance between the two conflicting interests in order to ensure that they do not compromise the interests of the open population health.

The other issue of concern is that of research and development (R&D) investment. Despite India being a country with great advance in terms of generic drug production, it is relatively low in terms of the discovery of new chemical entities and breakthrough therapies in comparison to developed countries. One of the factors that have contributed to this gap is the cost and risk of pharmaceutical R&D. The existing system of patents, where the focus on evergreening is prevented, can even deter incremental innovation, which can also be crucial in enhancing the efficacy and delivery of drugs. To this end, policies which encourage radical and incremental innovation like increased public financing, tax incentives and public-corporate collaborations are needed.

Regulatory issues also complicate the surrounding. A good regulatory system and unremitting control of the pharmaceutical products and their constituents provide quality, safety and effectiveness to the ever-increasing percentage of these products. Despite the fact that India has formed a desirable regulatory standard, the flourishing pharmaceutical industry needs an ongoing development of regulatory capacity, transparency and enforcement. In addition, the international regulatory standards can help the Indian pharmaceutical products to enter the international market and maintain its own standards of quality.

Going forward, the policy of patent and pharmaceutical policy in India should take shape towards flexibility and inclusivity. The policy-makers should also consider the possibility of changing the legal language to deal with the new technologies such as gene therapies, nanomedicine,

and digital health innovations (Rao and Appaji, 2025). This will require an increased collaboration among law professionals, scientists and business representatives to build a pro-active and adaptable system (Shukla and Jakhar, 2026). In addition, priority of policies should be to support study of neglected diseases, and equal provision of novel therapies.

Conclusion

The patent law regime in India is regarded as a unique and strong precedent in the international pharmaceutical sector that may demonstrate how the principle of intellectual property rights may be reconciled with the domestic health concerns. India has been in a position to offer viable mechanisms to deter the abuse of patent regimes and simultaneously foster the emergence of a robust and competitive generic drug business by well-established legal protection mechanisms such as the Section 3(d), compulsory licensing and patent opposition regimes.

Combining the principles of law with the pharmaceutic standards have guaranteed that generic medicines are not only cheap but also of high quality, safety and effectiveness. This has helped India to contribute significantly to the supply of life saving medicines to the domestic as well as the global society, especially those in the low and middle-income nations.

In the meantime, the article indicates that this balance is a process that should be taken care of in the long-term and should be continuously adapted to emerging problems. The dynamic nature of pharmaceutical innovation, the ever-increasing pressures in the global arena, and the need to increase R&D investment necessitate the implementation of a flexible and dynamic policy. It is also important that India continues refining its patent laws and regulations to get over these challenges without jeopardising its commitment to accessibility.

Therefore, what the Indian case must teach other nations is that in matters concerning the need to strike a balance between the needs of innovation and the needs of the populace, there are certain lessons to be learnt. India needs to focus on accessibility and scientific development since it can continue to be among the leaders in the world of generic pharmaceuticals, not to mention that it will be able to increase its innovation capacities with time.

REFERENCES

1. Gomase, V.S., Dhamane, S.P. and Jagdale, S.C., 2025. Intellectual Property Rights Effects on India's Pharmaceutical Industry. Recent Patents on Biotechnology.
2. Singh, B., Shastri, A., Mukherjee, B.N., Chutia, U. and Dutta, G., 2022. The effect of TRIPS implementation on Indian patent law: A pharmaceutical industry perspective: With special reference to healthcare industry.
3. Patel, B.D., Suthar, S.P., Mansuri, A.M. and Joshi, V.D., 2024. A Comparative Analysis of Generic Drug Assessment and Regulatory Approval in the USA, Europe and India. Chinese Journal of Applied Physiology, p.e20240029.
4. Kumar, S., 2024. Innovative drug discovery research by pharmaceutical companies in India and China. Journal of Medicinal Chemistry, 67(12), pp.9773-9775.
5. Ali, A. and Sinha, K., 2024. Regulatory Landscape for Generic Drugs in India: Assessing Quality, Safety, and Efficacy Standards. Biotechnology Law Report, 43(3), pp.131-141.
6. Dash, D.K., Vaiswade, R. and Gupta, G., 2023. A review on the Indian patent system and its implication on the pharmaceutical industry. Journal of Health Science and Medical Research, 41(3), p.2023926.
7. Rao, B.S. and Appaji, P.V., 2025. Intellectual Property Rights in Pharmaceutical Industry: Theory and Practice. PharmaMed Press/BSP Books.
8. Singh, S., Singh, A., Prakash, R.C. and Yadav, R.K., 2025. Contemporary stance of compulsory licencing in the Indian pharmaceutical industry. Journal of Intellectual Property Rights (JIPR), 30(3), pp.361-375.
9. Shukla, N. and Jakhar, T., 2026. From patent reform to public health risk? Analysing India's 2024 patent amendments and their impact on access to medicines. Cogent Social Sciences, 12(1), p.2635165.
10. Bhattacharyya, S., Chaudhuri, B.R., Chatterjee, S. and Chakraborty, D., 2024. Pharmaceutical exports and patents in India–a systems approach. Indian Growth and Development Review, 17(3), pp.341-360.
11. Devi, T.M. and Harika, B., 2022. Analysis On Generic Medicine V. Patented Medicine. Journal of Positive School Psychology, 6(3).
12. Gupta, A. and Raza, A., 2023. Patent law and compulsory licensing: Indian perspective. Journal of Intellectual Property Rights, 29(1), pp.5-17.
13. Reddy, M.V., Ganesh, G.N.K., Babu, B., Jagadeesan, R. and MR, P.K., 2022. Risk assessment of failures in generic drug development and approval procedure under competitive generic drug therapy and patent challenge exclusivities provided by the United States Food and Drug Administration. Acta Marisiensis-Seria Medica, 68(1), pp.28-34.
14. Abbas, M.Z., 2023. Patent Laws and the Public Health Puzzle: Comparing India's Patent Opposition Model with the US and the EU Model. Indian J. Intell. Prop. L., 13, p.1.
15. Tenni, B., Lexchin, J., Phin, S., Kittitrakul, C. and Gleeson, D., 2023. Lessons from India and Thailand for Cambodia's future implementation of the TRIPS Agreement for pharmaceutical patents. The Journal of World Intellectual Property, 26(2), pp.166-194.
16. Jha, R., 2024. Pharmaceutical patents: Cathartic or inhibiting. The Journal of World Intellectual Property, 27(3), pp.428-445.

17. Parthasarthi, V., 2022. Analysis of Compulsory Licensing in India and its Perceived Impact During the Covid Era. GLS Law Journal, 4(2), pp.21-30.
18. Singh, B., 2023. Intellectual property rights, innovation and healthcare: harmonizing the legal provisions for healthcare and pharmaceutical industry. JIPRO: Journal of Intellectual Property, pp.58-67.
19. Sharma, A.K., Shrivastava, T.P., Singh, M.A., Ahuja, J. and Goyal, R.K., 2024. Regulations in India. In Global Regulations of Medicinal, Pharmaceutical, and Food Products (pp. 133-152). CRC Press.
20. Beerannavar, C.R. and Koshi, S.M., 2025. Regulatory and Strategic Challenges of Patent Evergreening in the MedTech Industry: An Analysis of Competition Law Implications. In Strategic Management, Regulatory Challenges, and Global Governance of MedTech (pp. 149-184). IGI Global Scientific Publishing.
21. Ali, A. and Sinha, K., 2023. A review of patent regimes on Health Biotechnology Innovation in India. Biotechnology Law Report, 42(1), pp.33-38.
22. Chakraborty, B. and Sourav, S., 2025. Patently Problematic: Innovation, Access, and the Road Ahead. GLC Mumbai Intellectual property rights journal, 1.
23. Abbas, M.Z., 2024. India's Use of Patent Opposition Mechanism as an Access to Drugs Strategy: An Empirical Analysis. Journal of Intellectual Property Rights, 29(4), pp.253-264.
24. Siwal, A., 2022. Coverage-Disclosure Conundrum and Future of Species Patents in India. Journal of Intellectual Property Rights (JIPR), 27(5), pp.309-316.
25. Ilin, D.V. and Lazanyuk, I.V., 2024. Indian pharmaceutical market: a way towards leadership in generics. Вестник Российского университета дружбы народов. Серия: Экономика, 32(4), pp.725-743.
26. Krishna, P.D., Sujatha, D.K. and Veeranna, B., 2022. Indian Pharmaceutical Product Protection by Utilizing Intellectual Property Rights. Indian Journal of Pharmaceutical Education & Research, 56(4).
27. Ravi, S., Jadhav, S. and Ghooi, R., 2023. Drug repurposing" policies and statutes: lessons from the COVID-19 pandemic: a review. Indian J Pharm Educ Res, 57, pp.301-7.
28. Kumar, S. and Sahai, A., 2022. Indian Competition Law Regime vis-a-vis Healthcare & Pharmaceutical Sector: An Analysis during COVID 19. Part 1 Indian J. Integrated Rsch. L., 2, p.1.
29. Kumutha, N., Amutha, N. and Venkatesh, G.S., 2022. Compulsory licensing of patents. Pharmaceutical Patent Analyst, 11(6), pp.225-231.